Due to system maintenance, the application system, application review by the Data Access Committee will be unavailable during the following period.
Schedule: October 5th (Mon), 2026, 9:00 - October 7th (Wed), 2026, 15:00 (JST)
We apologize for any inconvenience this may cause and appreciate your understanding.

We are currently receiving a large number of applications for data submission, and the review process is taking longer than usual.We sincerely apologize for the delay and kindly ask for your understanding. When submitting an application, we would greatly appreciate it if you could allow sufficient time for the processing.

Following a change to our organizational structure effective April 1, 2026, this division has been renamed from the "Database Center for Life Science, Joint Support-Center for Data Science Research" to the "Database Division for Life Science (DBCLS), BioData Science Initiative (BSI), National Institute of Genetics (NIG)". Where the former name still appears in the guidelines, please read it as the new name.

Research ID

hum0194-v1Release info

Latest

Research title

Molecular mechanisms of drug resistance in cancer

Research overview

Aims: To study the molecular mechanisms of drug resistance in lung cancer patients by using of their tumor cells
Methods: Target Capture Sequencing
Participants/materials: tumor tissues from ROS1-rearranged non-small cell lung cancer patients
URL: N/A

Datasets

Cart	Dataset ID	Type of data	Analysis method	Access criteria	Date published
	JGAD000272	NGS (Target Capture)	Targeted DNA sequencing	Controlled-access (Type I)	2020-09-28

Data provider

Principal investigator: Ryohei Katayama
Affiliation: Japanese Foundation for Cancer Research

Research projects

Name	URL
Div of Exp Chemother, Cancer Chemotherapy Center	https://www.jfcr.or.jp/english/chemotherapy/department/fundamental/index.html (opens in a new tab)

Grants

Name	Title	Project number
KAKENHI Grant-in-Aid for Scientific Research (B)	Drug resistance mechanisms and therapeutic strategies in rare driver oncogene positive cancers	16H04715
KAKENHI Grant-in-Aid for Scientific Research (B)	Molecular mechanisms of drug tolerant persister cells emergence after molecular target therapy in lung cancer	19H03524
KAKENHI Grant-in-Aid for Scientific Research (A)	Molecular analysis of acquired resistance to targeted therapies and search for overcoming drugs	15H02368
KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)	Integrated analysis and regulation of cellular diversity for disease treatment	17H06327
Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED)	Development of combined strategy for treatment of drug-insensitive cancers with advanced technologies in interdisciplinary research areas	JP19cm0106203
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED)	Mechanisms of checkpoint inhibitor resistance through secretable immunosuppressive variants	JP19ck0106472

Related publications

Title	DOI	Dataset ID
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models	https://doi.org/10.1038/s41467-019-11496-z (opens in a new tab)	JGAD000272

Controlled access users

Principal investigator	Affiliation	Country/Region	Research title	Period of data use	Dataset ID
Hirofumi Nakaoka	Department of Cancer Genome Research, Sasaki Institute	Japan	Genetic analysis of lung cancer	2022-08-17 – 2026-07-23	JGAD000272